SONOVA Hldg AG/ADR (NASDAQ: BLFS) and BioLife Solutions (NASDAQ:BLFS) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, institutional ownership and profitability.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for SONOVA Hldg AG/ADR and BioLife Solutions, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SONOVA Hldg AG/ADR 0 0 0 0 N/A
BioLife Solutions 0 0 3 0 3.00

BioLife Solutions has a consensus target price of $22.33, indicating a potential upside of 17.05%. Given BioLife Solutions’ higher probable upside, analysts plainly believe BioLife Solutions is more favorable than SONOVA Hldg AG/ADR.

Earnings and Valuation

This table compares SONOVA Hldg AG/ADR and BioLife Solutions’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
SONOVA Hldg AG/ADR $2.43 billion 5.51 $354.51 million N/A N/A
BioLife Solutions $11.02 million 28.50 -$2.51 million ($0.21) -90.86

SONOVA Hldg AG/ADR has higher revenue and earnings than BioLife Solutions.

Risk and Volatility

SONOVA Hldg AG/ADR has a beta of 0.06, suggesting that its stock price is 94% less volatile than the S&P 500. Comparatively, BioLife Solutions has a beta of 1.46, suggesting that its stock price is 46% more volatile than the S&P 500.

Insider & Institutional Ownership

0.2% of SONOVA Hldg AG/ADR shares are held by institutional investors. Comparatively, 27.8% of BioLife Solutions shares are held by institutional investors. 38.5% of BioLife Solutions shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Dividends

SONOVA Hldg AG/ADR pays an annual dividend of $0.30 per share and has a dividend yield of 0.7%. BioLife Solutions does not pay a dividend.

Profitability

This table compares SONOVA Hldg AG/ADR and BioLife Solutions’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
SONOVA Hldg AG/ADR N/A N/A N/A
BioLife Solutions 1.76% 2.24% 1.92%

Summary

BioLife Solutions beats SONOVA Hldg AG/ADR on 9 of the 12 factors compared between the two stocks.

About SONOVA Hldg AG/ADR

Sonova Holding AG designs, develops, manufactures, and distributes hearing systems for adults and children with hearing impairment. It offers hearing instruments, cochlear implants, wireless communication products, and rechargeable hearing aids, as well as professional audiological services. The company provides hearing instruments under the Phonak, Unitron, and Hansaton brand names; cochlear implants under the Advanced Bionics brand name; and professional audiological services under the Connect Hearing brand name. Sonova Holding offers its products through a sales and distribution network, which comprise approximately 50 Sonova-owned wholesale companies and 100 independent distributors; and AudioNova retail network of approximately 3,300 locations in 12 markets. It operates in the Americas, Europe, the Middle East, Africa, and the Asia/Pacific. The company was formerly known as Phonak Holding AG and changed its name to Sonova Holding AG in August 2007. Sonova Holding AG was founded in 1947 and is headquartered in Stäfa, Switzerland.

About BioLife Solutions

BioLife Solutions, Inc. develops, manufactures, and markets patented tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced, and delayed-onset cell damage and death. The company offers HypoThermosol FRS, a hypothermic storage and shipping media product to mitigate temperature-induced molecular cell stress responses that occur during chilling and re-warming of biologics, intermediate products, and final cell products intended for research and clinical applications; and CryoStor cryopreservation freeze media products to mitigate temperature-induced molecular cell stress responses during freezing and thawing. It also provides BloodStor freeze media products, such as BloodStor 55-5 and BloodStor 100 for cryopreservation of stem and other cells isolated from umbilical cord and peripheral blood, and bone marrow; and cell thawing media, which offers Dextran and saline for washing cryopreserved cells and tissues to dilute or remove cryoprotectants. In addition, the company provides custom product formulation and packaging services; and contract aseptic manufacturing formulation, filling, and finishing services for liquid media products. It markets its products to the regenerative medicine, bio-banking, and drug discovery markets, including hospital-based stem cell transplant centers, pharmaceutical companies, cord blood and adult stem cell banks, and hair transplant centers, as well as suppliers of cells to the drug discovery, toxicology testing, and diagnostic markets. The company markets and sells its products directly using its sales force, as well as through biolifesolutions.com; and through various regional distributors. BioLife Solutions, Inc. was founded in 1987 and is headquartered in Bothell, Washington.

Receive News & Ratings for SONOVA Hldg AG/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SONOVA Hldg AG/ADR and related companies with MarketBeat.com's FREE daily email newsletter.